Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Targeting T cells to treat atherosclerosis: odyssey from bench to bedside

Open access
Bullenkamp, Jessica, Dinkla, Sip, Kaski, Juan Carlos, Dumitriu, Ingrid E. · 2016 · European Heart Journal - Cardiovascular Pharmacotherapy

Abstract

More than 150 years from the initial description of inflammation in atherosclerotic plaques, randomized clinical trials to test anti-inflammatory therapies in atherosclerosis have recently been initiated. Lymphocytes and macrophages are main participants in the inflammatory response in atherosclerosis. T lymphocytes operate mainly by exerting strong influences on the function of many cells in the immune system and beyond, and co-ordinating their interactions. Importantly, T lymphocytes are not a homogenous population, but include several subsets with specialized functions that can either promote or suppress inflammation. The interactions between these T-lymphocyte subsets have critical consequences on the course and outcome of inflammation. The complexity of the inflammatory response in atherosclerosis poses significant challenges on translating experimental findings into clinical therapies and makes the journey from bench to bedside an arduous one. Here, we summarize recent advances on the role of CD4(+) T cells in the inflammatory process in atherosclerosis and discuss potential therapies to modulate these lymphocytes that may provide future breakthroughs in the treatment of atherosclerosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ehjcvp/pvw001

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of cardinal features and potential strategies to target CD28null and regulatory T-cell lymphocytes in atherosclerosis. CD28null T cells expand in the circulation and atherosclerotic plaques in patients with acute coronary syndrome. These cells produce high levels of inflammatory cytokines (interferon-γ and tumour necrosis factor-α) and express and release cytotoxic molecules (perforin and granzyme B). The production of cytokines and cytotoxic molecules is modulated by co-stimulatory receptors OX40 and 4-1BB, which are up-regulated on CD28null T cells. Moreover, CD28null T cells are resistant to apoptosis due to reduction in apoptotic molecules Fas, Bim, and Bax, which underlies the expansion of this cell subset in acute coronary syndrome patients. Several strategies have been proposed to reduce the number and/or function of CD28null T cells such as tumour necrosis factor-α inhibition, statins, sensitization to apoptosis, and inhibition of co-stimulation (CTLA4-Ig, anti-OX40, and anti-4-1BB antibodies). Regulatory T cells have crucial roles in counteracting the actions of inflammatory T lymphocytes such as CD28null T cells. Redundant mechanisms enable regulatory T cells to suppress inflammation and T-cell actions among which are the production of anti-inflammatory cytokines (interleukin-10 and transforming growth factor-β), CTLA-4-mediated suppression, and interference with metabolic pathways (conversion of ATP into adenosine, which has anti-inflammatory properties). On-going experimental and clinical work is testing various strategies to boost the number and/or the function of circulating or intraplaque regulatory T cells such as adoptive transfer of regulatory T cells expanded in vitro, vaccination protocols that induce expansion of naturally occurring regulatory T cells or conversion of conventional CD4+ T cells into regulatory T cells, and blockade of inflammatory cytokines (tumour necrosis factor-α and interleukin-6).
Figure 1 Overview of cardinal features and potential strategies to target CD28null and regulatory T-cell lymphocytes in atherosclerosis. CD28null T cells expand in the circulation and atherosclerotic plaques in patients with acute coronary syndrome. These cells produce high levels of inflammatory cytokines (interferon-γ and tumour necrosis factor-α) and express and release cytotoxic molecules (perforin and granzyme B). The production of cytokines and cytotoxic molecules is modulated by co-stimulatory receptors OX40 and 4-1BB, which are up-regulated on CD28null T cells. Moreover, CD28null T cells are resistant to apoptosis due to reduction in apoptotic molecules Fas, Bim, and Bax, which underlies the expansion of this cell subset in acute coronary syndrome patients. Several strategies have been proposed to reduce the number and/or function of CD28null T cells such as tumour necrosis factor-α inhibition, statins, sensitization to apoptosis, and inhibition of co-stimulation (CTLA4-Ig, anti-OX40, and anti-4-1BB antibodies). Regulatory T cells have crucial roles in counteracting the actions of inflammatory T lymphocytes such as CD28null T cells. Redundant mechanisms enable regulatory T cells to suppress inflammation and T-cell actions among which are the production of anti-inflammatory cytokines (interleukin-10 and transforming growth factor-β), CTLA-4-mediated suppression, and interference with metabolic pathways (conversion of ATP into adenosine, which has anti-inflammatory properties). On-going experimental and clinical work is testing various strategies to boost the number and/or the function of circulating or intraplaque regulatory T cells such as adoptive transfer of regulatory T cells expanded in vitro, vaccination protocols that induce expansion of naturally occurring regulatory T cells or conversion of conventional CD4+ T cells into regulatory T cells, and blockade of inflammatory cytokines (tumour necrosis factor-α and interleukin-6).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 1

  1. 10.1002/1529-0131(199812)41:12<2108::AID-ART5>3.0.CO;2-Q · DOI

Cited by

See all 38

Metadata

Authors
Bullenkamp, J., Dinkla, S., Kaski, J. C., & Dumitriu, I. E.
Affiliations
St George's, University of London (GB)
Corresponding author
Dumitriu, Ingrid E.
Venue
European Heart Journal - Cardiovascular Pharmacotherapy
Published
2016-01-24
Volume
2
Issue
3
Pages
194-199
ISSN
  • 2055-6837 (ISSN-L)
  • 2055-6845
OpenAlex
W2297695250
Cited by
38
References
60
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 2 · 2021: 3 · 2020: 9 · 2019: 7 · 2018: 5 · 2016: 3
FWCI
0.48
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • European Heart Journal - Cardiovascular Pharmacotherapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • St George's Online Research Archive (St George's University of London) (submittedVersion, other-oa)
  • HighWire Press Open Archive (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Funders
  • British Heart Foundation (PG/10/50/28434, PG/13/24/30115, PG/14/18/30724)
  • St George's Hospital Charity
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
Keywords
atherosclerosis, T cells, CD4+ T cells, inflammation, anti-inflammatory therapy, T cell subsets, macrophages, lymphocytes, atherosclerotic plaque, immunomodulation, clinical translation
MeSH terms
Animals, Humans, T-Lymphocytes, CD4-Positive T-Lymphocytes, Atherosclerosis, T-Lymphocytes, Regulatory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting T cells to treat atherosclerosis: odyssey from bench to bedside. https://app.cochat.ai/papers/10.1093/ehjcvp/pvw001
The paper
Bullenkamp, J., Dinkla, S., Kaski, J. C., & Dumitriu, I. E. (2016). Targeting T cells to treat atherosclerosis: odyssey from bench to bedside. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvw001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.